Antibody Target FDA-approved Approval in Mechanism of
indication Europe* action
Naked Antibodies : solid malignancies Trastuzumab ERBB2 ERBB2-positive breast cancer, as Similar Inhibition of (Herceptin; a single agent or in combination ERBB2 Genentech): with chemotherapy for adjuvant signaling and humanized IgG1 or palliative treatment ADCC
ERBB2- positive gastric or gastro-
oesophageal junction carcinoma as first-line treatment in combination with cisplatin and capecitabine or 5-fluorouracil Bevacizumab (Avastin; VEGF For first-line and second line Similar Inhibition of Genentech/Roche) : treatment of metastatic colon VEGF signalling humanized IgG1 cancer, in conjuction with 5- fluorouracil-based chemoterapy; for first-line treatment of advanced NSCLC, in combination with carboplatin and paclitaxel, in patients who have not yet received chemotherapy; as asible agent in adult patients with glioblastoma whose tumour has progressed after initial treatment; and in conjuction with IFNα to trat metastatic kidney cancer Cetuximab EGFR in combination with radiation Similar Inhibition of (Erbitux;Bristol▪Squib therapy for the initial treatment EGFR signalling b): chimeric of locally or regionally advanced and ADCC human▪murine igG1 SCCHN; as a single agent for patients with SCCHN for whom prior platinum▪based therapy has failed; and palliative treatment of pretreated metastatic EGFR▪positive colorectal cancer Panitumumab(vectibix EGFR As a single agent for the Similar Inhibition of ;Amgen): human IgG2 treatment of pretreated EGFR signalling EGFR▪expressing,metastatic colorectal carcinoma Ipilimumab CTLA4 For the treatment of Similar Inhibition if (Yervoy;Bristol▪Myers unresectable or metastatic CTLA4 Squibb): IgG1 melanoma signalling